![Helus Pharma Inc [Common Shares] Logo](https://image.parqet.com/security/CA4234921076)
Loading quotes...
Forecast
The analysts' average price target is €19.61 (+106.86%). The median is €14.26 (+50.42%).
| Buy |
4 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -26.47k | - |
| Net profit | -40.84m | 95.60% |
| EBITDA | -41.89m | 100.77% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €595.48m |
Number of shares | 61.98m |
52-week high/low | €13.50 - €3.35 |
| Dividends | No |
Beta | 0.54 |
P/E ratio | -2.58 |
PEG ratio | -0.12 |
P/B ratio | 2.34 |
P/S ratio | 0.00 |
Company profile
| Name | Helus Pharma Inc [Common Shares] |
| CEO | Michael I. Halstead |
| Employees | 100 |
